38% Lower Worsening-Heart-Failure or CV-Death Risk With Tirzepatide
A plain-English review of the SUMMIT trial, where tirzepatide reduced a composite of worsening heart failure or cardiovascular death in obesity-related HFpEF.
Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide and 15.3% with placebo (hazard ratio, 0.62).
731 adults with obesity and heart failure with preserved ejection fraction, with an ejection fraction of at least 50%; Median follow-up of 104 weeks. Read the linked peer-reviewed source for the full methodology, findings, and limitations.